Journal of Rehabilitation Research Current Updates
Between Silence and Senescence: Decoding the Accelerated Aging Phenotype and Im-munological Paradox in Primary Ovarian Insufficiency Through a Multi-Omics Lens
Abstract
Aqsa Akram and Namra Ashfaq
Background: Primary Ovarian Insufficiency (POI), defined by the European Society of Human Reproduction and Embryology (ESHRE) as oligomenorrhea or amenorrhea for at least four months with two serum FSH measurements exceeding 25 IU/L more than four weeks apart in women under 40, affects approximately 1–3.7% of the global female population [1]. Beyond its reproductive consequences, POI is increasingly understood as a systemic accelerated aging event---a state in which the biological age of a woman in her late twenties or thirties approximates that of a woman in her early-to-mid fifties, as evidenced by converging multi-omics signatures across proteomic, metabolomic, and inflammatory dimensions [2,3].
Objective: To characterize the multi-omics aging signature in POI, compare it quantitatively and qualitatively with natural menopause, and critically examine the dual role of the immune system as both an agent of follicular destruction and a potential mediator of ovarian repair and regeneration.
Methods: Structured narrative synthesis of peer-reviewed publications from October 2023 to February 2026, retrieved from PubMed, EMBASE, and Cochrane, employing proteomic arrays, untargeted and targeted metabolomic profiling, multiplex cytokine panels, single-cell RNA sequencing, epigenetic clock analyses, and immune phenotyping studies in women with POI and comparator populations.
Results: POI demonstrates a canonical Senescence-Associated Secretory Phenotype (SASP) proteomic signature with 73% overlap with the natural postmenopausal proteome, ceramide and mitochondrial energy dysregulation equivalent to women aged 52–58, IDO1-mediated tryptophan–kynurenine pathway activation producing quinolinic acid neurotoxicity, and chronic inflammaging with IL-6 elevated 3.2-fold, TNF-α 2.8-fold, and IFN-γ 10.3-fold in autoimmune POI versus premenopausal controls. Epigenetic clocks reveal biological age advancement of 8–15 years. Simultaneously, the immune system harbors regenerative capacity through M2 macrophage polarization, Treg expansion, ILC2-mediated stromal remodeling, and mesenchymal stem cell (MSC)-facilitated immune reset [4-10].
Conclusions: POI constitutes an accelerated biological aging state that is distinct from, but substantially convergent with, natural menopause. Clinical screening for osteoporosis, cardiovascular disease, and neurocognitive decline must be recalibrated to biological rather than chronological age from the time of diagnosis. Immune modulation---through low-dose IL-2, MSC infusion, and targeted biologics---represents an underexplored but rapidly maturing therapeutic frontier with early- phase trial evidence of follicular rescue.